RS62935B1 - Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera - Google Patents

Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera

Info

Publication number
RS62935B1
RS62935B1 RS20220165A RSP20220165A RS62935B1 RS 62935 B1 RS62935 B1 RS 62935B1 RS 20220165 A RS20220165 A RS 20220165A RS P20220165 A RSP20220165 A RS P20220165A RS 62935 B1 RS62935 B1 RS 62935B1
Authority
RS
Serbia
Prior art keywords
riluzole
immunotherapies
analogs
prodrugs
treat cancers
Prior art date
Application number
RS20220165A
Other languages
English (en)
Serbian (sr)
Inventor
Vladimir Coric
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of RS62935B1 publication Critical patent/RS62935B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20220165A 2016-05-20 2017-05-19 Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera RS62935B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339433P 2016-05-20 2016-05-20
EP17800310.9A EP3458053B1 (fr) 2016-05-20 2017-05-19 Utilisation du riluzole, de promédicaments du riluzole ou d'analogues du riluzole avec des immunothérapies pour traiter les cancers
PCT/US2017/033688 WO2017201501A1 (fr) 2016-05-20 2017-05-19 Utilisation du riluzole, de promédicaments du riluzole ou d'analogues du riluzole avec des immunothérapies pour traiter les cancers

Publications (1)

Publication Number Publication Date
RS62935B1 true RS62935B1 (sr) 2022-03-31

Family

ID=60326148

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20240502A RS65474B1 (sr) 2016-05-20 2017-05-19 Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
RS20220165A RS62935B1 (sr) 2016-05-20 2017-05-19 Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20240502A RS65474B1 (sr) 2016-05-20 2017-05-19 Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera

Country Status (26)

Country Link
US (3) US20190175731A1 (fr)
EP (3) EP3458053B1 (fr)
JP (4) JP7169195B2 (fr)
KR (2) KR102369735B1 (fr)
CN (2) CN109890387B (fr)
AU (2) AU2017266951B2 (fr)
BR (1) BR112018073781A2 (fr)
CA (1) CA3025019A1 (fr)
CY (1) CY1124999T1 (fr)
DK (2) DK3458053T3 (fr)
EA (1) EA201892587A1 (fr)
ES (2) ES2905823T3 (fr)
FI (1) FI4019019T3 (fr)
HR (1) HRP20220237T1 (fr)
HU (1) HUE058184T2 (fr)
IL (2) IL292302B2 (fr)
LT (2) LT3458053T (fr)
MX (2) MX2018013868A (fr)
PH (1) PH12018502409A1 (fr)
PL (1) PL3458053T3 (fr)
PT (2) PT3458053T (fr)
RS (2) RS65474B1 (fr)
SG (1) SG11201809669RA (fr)
SI (1) SI3458053T1 (fr)
WO (2) WO2017201502A1 (fr)
ZA (1) ZA201807398B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (fr) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
MX2017011196A (es) * 2015-03-03 2018-05-22 Biohaven Pharm Holding Co Ltd Farmacos precursores de riluzol y sus usos.
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
WO2017062354A1 (fr) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Polythérapie à l'aide d'inhibiteurs de glutaminase et agents immuno-oncologiques
JP7169195B2 (ja) * 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
EP3532504A1 (fr) * 2016-10-28 2019-09-04 Bristol-Myers Squibb Company Méthodes de traitement du carcinome urothélial au moyen d'un anticorps anti-pd -1
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
WO2019040780A1 (fr) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. Anticorps anti-b7-h4 et leurs procédés d'utilisation
US20210177841A1 (en) * 2017-11-03 2021-06-17 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
BR112020016256A2 (pt) * 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
SG11202100385YA (en) * 2018-07-22 2021-02-25 Biohaven Therapeutics Ltd Use of riluzole prodrugs to treat alzheimer's disease
EP3914266A4 (fr) * 2019-01-24 2022-12-07 University of Cincinnati Co-cultures d'organoïdes tumoraux autologues et de cellules immunitaires et leurs procédés d'utilisation en tant que modèles prédictifs pour le traitement du cancer du pancréas
EP3983084A1 (fr) * 2019-06-12 2022-04-20 Vanderbilt University Inhibiteurs de transport d'acides aminés et utilisations associées
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
JP7431412B2 (ja) 2019-12-23 2024-02-15 三菱マテリアル株式会社 被覆電線の分離方法
CA3175322A1 (fr) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Vesicules extracellulaires de conception pour le traitement de l'excitotoxicite
KR102441650B1 (ko) * 2020-07-31 2022-09-08 서울대학교병원 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법
WO2022197767A1 (fr) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Procédés pour améliorer la survie chez des patients atteints d'un cancer du poumon par l'intermédiaire d'une oncoprotection de kétamine
EP4373525A1 (fr) * 2021-07-21 2024-05-29 Viracta Subsidiary, Inc. Combinaisons de traitement pour le cancer
TW202406539A (zh) * 2022-04-21 2024-02-16 大陸商北京加科思新藥研發有限公司 藥物組合及其用途
CN116492322A (zh) * 2023-05-10 2023-07-28 徐州医科大学 小分子阻滞剂mem在制备治疗肿瘤药物的应用

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209066A (fr) 1921-03-01 Tschirner Frederick Conversion du potassium a l'etat soluble
US7812A (en) 1850-12-03 Nail-plate feeder and turner
US135A (en) 1837-03-03 Jesse j
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2166891C (fr) 1993-07-09 2001-07-03 Sang K. Wong Methode pour l'obtention de formes posologiques par lyophylisation
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2001502325A (ja) 1996-10-11 2001-02-20 ブリストル―マイヤーズ・スクイブ・カンパニー 免疫調整の方法および組成物
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
EP1325932B9 (fr) 1997-04-07 2006-07-19 Genentech, Inc. Anticorps anti-VEGF
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2263216T3 (es) 1997-07-25 2006-12-01 Alpex Pharma S.A. Procedimiento para la preparacion de un granulado adecuado para la preparacion de comprimidos solubles en la boca rapidamente disgregables.
CA2349203C (fr) 1998-11-20 2013-05-21 Rtp Pharma Inc. Microparticules dispersibles stabilisees par phospholipides
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN100482281C (zh) 1999-06-25 2009-04-29 基因技术股份有限公司 抗ErbB抗体-类美坦素偶联物在制备药物中的应用
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ATE371442T1 (de) 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
AU2003213687A1 (en) 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
JP4871125B2 (ja) 2003-07-02 2012-02-08 イナート・ファルマ Ｎｋ細胞活性を調節するための組成物および方法
DK1648507T3 (en) 2003-07-24 2017-05-01 Innate Pharma Sa PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP1784396B8 (fr) 2004-08-26 2011-04-20 Pfizer Inc. Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
CN101102791B (zh) 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
SI1836225T1 (sl) 2005-01-06 2012-06-29 Novo Nordisk As Kir vezujoäśa sredstva in postopki za njihovo rabo
EP1835929B8 (fr) 2005-01-06 2016-07-27 Novo Nordisk A/S Procédés et traitements combinés anti-kir
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP1744020A1 (fr) 2005-07-14 2007-01-17 Siemens Aktiengesellschaft Procédé de démarrage d'une installation de turbines à vapeur
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1963302B1 (fr) 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphes d'un inhibiteur de c-met/hgfr
BRPI0619424B1 (pt) 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
CA2647282A1 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
EP2604278B1 (fr) 2007-01-11 2017-04-12 Novo Nordisk A/S Anticorps anti-kir, formulations et utilisations associées
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
EP2175884B8 (fr) 2007-07-12 2017-02-22 GITR, Inc. Thérapies combinées utilisant des molécules de liaison au gitr
RS53760B1 (en) 2007-10-01 2015-06-30 Bristol-Myers Squibb Company HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
WO2010065939A1 (fr) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
CN103298831A (zh) 2010-11-22 2013-09-11 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
JP6322413B2 (ja) 2011-03-10 2018-05-09 プロヴェクタス ファーマテック，インク． 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
KR20140041906A (ko) 2011-08-02 2014-04-04 화이자 인코포레이티드 암의 치료에 사용하기 위한 크리조티닙
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
BR112014011144A2 (pt) 2011-11-09 2017-05-16 Bristol Myers Squibb Co tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
US10864271B2 (en) * 2012-02-15 2020-12-15 Rutgers, The State University Of New Jersey Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
WO2013138753A1 (fr) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
WO2013192610A2 (fr) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Promédicaments du riluzole et leur procédé d'utilisation pour le traitement d'une sclérose latérale amyotrophique
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20150290316A1 (en) 2012-10-02 2015-10-15 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3508502B1 (fr) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combinaison d'anticorps anti-lag-3 et anti-pd-1 pour traiter des tumeurs
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
KR102433464B1 (ko) 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
WO2016007235A1 (fr) * 2014-07-11 2016-01-14 Genentech, Inc. Anticorps anti-pd-l1 et leurs utilisations
US20160073759A1 (en) * 2014-09-15 2016-03-17 Beauty Solutions Agency Inc. Nail covering
JP7305300B2 (ja) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
US10235906B2 (en) * 2014-11-18 2019-03-19 Maximum Fidelity Surgical Simulations, LLC Post mortem reconstitution of circulation
US20160140879A1 (en) * 2014-11-19 2016-05-19 David Hananel Anatomically correct movement or deformation of simulated bodily structures
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
MX2017011196A (es) 2015-03-03 2018-05-22 Biohaven Pharm Holding Co Ltd Farmacos precursores de riluzol y sus usos.
KR20170138477A (ko) 2015-04-17 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2017059224A2 (fr) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combinaison d'un inhibiteur de btk et d'un inhibiteur de point de contrôle pour le traitement de cancers
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用

Also Published As

Publication number Publication date
AU2021221560B2 (en) 2023-10-26
JP7224186B2 (ja) 2023-02-17
EP3458054B1 (fr) 2022-02-23
CY1124999T1 (el) 2023-01-05
SI3458053T1 (sl) 2022-04-29
CN109890387A (zh) 2019-06-14
EP3458053A1 (fr) 2019-03-27
EA201892587A1 (ru) 2019-04-30
KR20220029772A (ko) 2022-03-08
EP3458053A4 (fr) 2019-11-20
JP2022191256A (ja) 2022-12-27
CN109890387B (zh) 2022-06-14
AU2021221560A1 (en) 2021-09-16
HRP20220237T1 (hr) 2022-04-29
EP3458053B1 (fr) 2021-12-08
RS65474B1 (sr) 2024-05-31
AU2017266951A1 (en) 2018-11-22
ZA201807398B (en) 2020-05-27
AU2017266951B2 (en) 2021-05-27
EP3458054A4 (fr) 2019-10-02
BR112018073781A2 (pt) 2019-02-26
ES2912131T3 (es) 2022-05-24
EP4019019B1 (fr) 2024-02-07
KR102525527B1 (ko) 2023-04-24
IL262849B (en) 2022-05-01
KR20190009334A (ko) 2019-01-28
KR102369735B1 (ko) 2022-03-02
EP3458054A1 (fr) 2019-03-27
WO2017201502A1 (fr) 2017-11-23
PT3458053T (pt) 2022-02-01
HUE058184T2 (hu) 2022-07-28
WO2017201501A1 (fr) 2017-11-23
CA3025019A1 (fr) 2017-11-23
US20230310595A1 (en) 2023-10-05
IL292302B2 (en) 2023-10-01
ES2905823T3 (es) 2022-04-12
PL3458053T3 (pl) 2022-04-25
PT4019019T (pt) 2024-05-13
JP7169195B2 (ja) 2022-11-10
US20190290619A1 (en) 2019-09-26
JP2023012508A (ja) 2023-01-25
SG11201809669RA (en) 2018-11-29
JP7493569B2 (ja) 2024-05-31
IL292302B1 (en) 2023-06-01
PH12018502409A1 (en) 2019-04-08
US11400155B2 (en) 2022-08-02
MX2022010377A (es) 2022-09-21
CN115350263A (zh) 2022-11-18
EP4019019A1 (fr) 2022-06-29
IL292302A (en) 2022-06-01
US20190175731A1 (en) 2019-06-13
FI4019019T3 (fi) 2024-05-14
JP2019516712A (ja) 2019-06-20
IL262849A (en) 2018-12-31
JP2019516711A (ja) 2019-06-20
LT4019019T (lt) 2024-06-25
DK4019019T3 (da) 2024-05-06
MX2018013868A (es) 2019-02-21
LT3458053T (lt) 2022-02-25
DK3458053T3 (da) 2022-02-21

Similar Documents

Publication Publication Date Title
HUE058184T2 (hu) Riluzol, riluzol prodrugok vagy riluzol analógok felhasználása immunterápiákkal rák kezeléséhez
IL286888A (en) Use of pyridofidine to treat depression and anxiety
HK1232086A1 (zh) 行李件
IL253197A0 (en) Methods for the treatment of sphingosine-1-phosphate receptor 1-related conditions
HUE050747T2 (hu) Poggyász
IL252283A0 (en) Sublingual administration of riluzole
HK1252816A1 (zh) Tlr8激活劑治療癌症的應用
HK1232087A1 (zh) 行李件
HK1259445A1 (zh) 治療癌症的組合
HK1245033A1 (zh) 行李箱
PT3334734T (pt) Forma c de avibactam sódico
IL274532A (en) Using the prodrug riluzole to treat ataxias
IL266087A (en) Use of itolizumab to reduce cd6 phosphorylation
HK1256902A1 (zh) 氯犬尿氨酸的前體藥物
GB201517784D0 (en) Production of graphene
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
GB2537419B (en) Accumulation of floating-point values
PL3515418T3 (pl) Zastosowanie inhibitorów C-Met w leczeniu nowotworów złośliwych z mutacjami MET
GB2550166B (en) Improvements to letter-plates
GB201621641D0 (en) Improvements relating to masking
ZA201704625B (en) Dewatering of sulphur
GB201604399D0 (en) Improvements relating to the treatment of plastics
HUE045876T2 (hu) Poggyászdarab
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib